{"id":242678,"date":"2025-06-18T13:21:57","date_gmt":"2025-06-18T13:21:57","guid":{"rendered":"https:\/\/pharmeasy.in\/blog\/?p=242678"},"modified":"2026-03-25T10:58:53","modified_gmt":"2026-03-25T10:58:53","slug":"mounjaro-vs-ozempic-our-endocrinologist-explains-the-difference","status":"publish","type":"post","link":"https:\/\/pharmeasy.in\/blog\/mounjaro-vs-ozempic-our-endocrinologist-explains-the-difference\/","title":{"rendered":"Mounjaro vs Ozempic: Our Endocrinologist Explains the Difference"},"content":{"rendered":"\n\n<\/head>

Table of Contents<\/p>\nToggle<\/span>

Introduction<\/a><\/li>
What Are Mounjaro and Ozempic?<\/a><\/li>
How Do They Work?<\/a><\/li>
Effectiveness in Type 2 Diabetes Management<\/a><\/li>
Weight Management Support<\/a><\/li>
Side Effects: Mounjaro vs Ozempic<\/a><\/li>
Cost and Availability: India and Global<\/a><\/li>
Who Might Benefit More from Mounjaro or Ozempic?<\/a><\/li>
Can You Switch from Ozempic to Mounjaro?<\/a><\/li>
Conclusion<\/a><\/li>
Frequently Asked Questions (FAQs)<\/a><\/li>
References<\/a><\/li><\/ul><\/nav><\/div>\n
<\/span>Introduction<\/strong><\/span><\/h2>\n\n\n\nIn India, an estimated 77 million adults are currently living with type 2 diabetes (T2DM)^{1<\/sup><\/a>. In many cases, lifestyle interventions such as diet modification and regular physical activity are sufficient in the early stages of T2DM. However, as the condition progresses, additional treatments may be needed to improve insulin sensitivity or enhance insulin secretion by the pancreas}^{2<\/sup><\/a>.\u00a0<\/p>\n\n\n\n}
In recent years, medications like Mounjaro and Ozempic have gained widespread attention for their effectiveness in managing type 2 diabetes (T2DM)^{3<\/sup><\/a>^,<\/sup>}^{4<\/sup><\/a>.^{<\/sup>Both tirzepatide and semaglutide (active ingredients of Mounjaro and Ozempic) are prescription medications approved by the Central Drugs Standard Control Organisation (CDSCO) and are prescribed under medical supervision}}^{5<\/sup><\/a>^,<\/sup>}^{6<\/sup><\/a>. While they share similarities in purpose, their mechanisms of action and dosing differ.\u00a0<\/p>\n\n\n\n}
In this article, we aim to provide a neutral, fact-based comparison of Mounjaro and Ozempic to help you better understand each option and support informed conversations with your doctor.\u00a0<\/p>\n\n\n\n
<\/span>What Are Mounjaro and Ozempic?<\/strong><\/span><\/h2>\n\n\n\n
Mounjaro (tirzepatide) and Ozempic (semaglutide) are both injectable medications designed to help manage T2DM in adults, alongside diet and exercise. Below are some brief details of these drug molecules-\u00a0<\/p>\n\n\n\n
Tirzepatide<\/a>\u00a0<\/strong><\/p>\n\n\n\n
\n
Approval: 2022 by the U.S. FDA and 2024 by CDSCO in India ^{5<\/sup><\/a><\/li>\n\n\n\n}
Manufacturer (Mounjaro): Eli Lilly and Company ^{5<\/sup><\/a><\/li>\n\n\n\n}
Class: Dual GIP and GLP-1 receptor agonist ^{7<\/sup><\/a>\u00a0<\/li>\n<\/ul>\n\n\n\n}
Semaglutide<\/a>\u00a0<\/strong><\/p>\n\n\n\n
\n
Approval: 2017 by the U.S. FDA and 2022 by CDSCO in India ^{6<\/sup><\/a>\u00a0<\/li>\n\n\n\n}
Manufacturer (Ozempic): Novo Nordisk ^{6<\/sup><\/a> (Semaglutide is available under other brands also)\u00a0<\/li>\n\n\n\n}
Class: GLP-1 receptor agonist ^{8<\/sup><\/a>\u00a0<\/li>\n<\/ul>\n\n\n\n}
Glucagon<\/a><\/strong>\u2010like peptide\u20101 (GLP\u20101) and gastric inhibitory polypeptide (GIP) are hormones that help regulate blood sugar after meals.\u00a0<\/p>\n\n\n\n
\n
GLP-1 increases insulin<\/a>, reduces glucagon, and slows digestion.\u00a0<\/li>\n\n\n\n
GIP also boosts insulin and may improve how the body uses it ^{9<\/sup><\/a>^,<\/sup>}^{10<\/sup><\/a>.\u00a0<\/li>\n<\/ul>\n\n\n\n}
Ozempic works by mimicking GLP-1 only, while Mounjaro targets both GLP-1 and GIP ^{7<\/sup><\/a>^,<\/sup>}^{8<\/sup><\/a>. This dual action makes Mounjaro potentially more effective for blood sugar control compared to Ozempic.\u00a0<\/p>\n\n\n\n}
<\/span>How Do They Work?<\/strong><\/span><\/h2>\n\n\n\n
$\"mounjaro$ <\/figure><\/div>\n\n\n
Both Mounjaro and Ozempic are medications (once weekly injections) that work by enhancing the body\u2019s natural hormone responses. Both should be used in conjunction with lifestyle and dietary changes for optimal results ^{3<\/sup><\/a>^,<\/sup>}^{7<\/sup><\/a>^,<\/sup>}^{8<\/sup><\/a>.\u00a0<\/p>\n\n\n\n}
Feature<\/strong>\u00a0<\/td> Mounjaro (tirzepatide)<\/strong>\u00a0<\/td> Ozempic (semaglutide)<\/strong>\u00a0<\/td><\/tr>
Drug Class\u00a0<\/td> GIP & GLP-1 receptor agonist\u00a0<\/td> GLP-1 receptor agonist\u00a0<\/td><\/tr>
Stimulates Insulin\u00a0<\/td> Yes (Enhanced due to dual hormone action)\u00a0<\/td> Yes (Via GLP-1 pathway)\u00a0<\/td><\/tr>
Suppresses Glucagon\u00a0<\/td> Yes\u00a0<\/td> Yes\u00a0<\/td><\/tr>
Lowers Blood Glucose\u00a0<\/td> Highly effective\u00a0<\/td> Effective\u00a0<\/td><\/tr>
Weight Loss Effect\u00a0<\/td> Substantial<\/td> Significant<\/td><\/tr>
Starting dose (decided by doctor)<\/td> Mounjaro 2.5mg Kwikpen<\/a> (2.5 mg \/ 0.5 ml)<\/td> <\/td><\/tr><\/tbody><\/table><\/figure>
<\/div>